*EMBARGOED All research presented at the 2021 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 24, 2021, at 3:30 pm EDT.
Oral 9 Treatment of Alcohol Use Disorder in Patients Admitted with Alcohol-Associated Liver Disease: A Retrospective Cohort Study
Author Insight from Patrick Twohig, MD, MPH, University of Nebraska Medical Center
What’s new here and important for clinicians?
Alcohol use disorder (AUD) medications are underutilized and were only prescribed in 21% of patients admitted with alcohol-associated liver disease (ALD) and AUD in our cohort.
Prescription of AUD medications resulted in a lower 1-year mortality in patients with alcohol-associated liver disease (4.2% vs. 20.9% in patients who were not prescribed medications).
What do patients need to know?
Alcohol use disorder is a major cause of health complications and death. Treatment has been shown to reduce alcohol consumption and subsequent risk of health complications. Only 21% of patients with alcohol use disorder and alcohol-associated liver disease were prescribed medical therapy in our cohort. One-year mortality was lower (4.2% vs. 20.9%) among those who received treatment for alcohol use disorder. There is a need to increase the utilization of medications to treat alcohol use disorder.
Patrick Twohig, MD, MPH, University of Nebraska Medical Center
patrick [dot] twohig [at] unmc [dot] edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org.